A Pilot Study Testing the Effects of Chemical Peels in Patients With Rosacea
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, randomized, one-site therapeutic trial of 15% trichloroacetic
acid (TCA) and 30% salicylic acid peels for rosacea. Two peels will be applied topically 4
weeks apart, and the study will end in 12 weeks. Endpoints include adverse affects within the
first 8 weeks and responses, which will be measured by Investigator Global Assessment (IGA),
a Rosacea Clinical Scorecard, and number of papular plus pustular lesions assessed every 4
weeks up to 12 weeks with high resolution photographs.
Treatment Dosage and administration
Study Drugs:
1. Trichloroacetic acid peel (15%) will be applied topically to the face for 2 treatments
at 4 week intervals.
2. Salicylic acid peel (30%) will be applied topically to the face for 2 treatments at 4
week intervals.
Duration of treatment: two single applications 4 weeks apart.
Endpoint: 12 weeks after first chemical peel treatment
Outcome measures:
- independent objective reviewer scoring of matched photographs before and after treatment
- number of papular and pustular lesions before and after treatment
- rosacea-specific patient quality of life survey responses before and after treatment
- Adverse effects such as peeling, redness, scaling, crusting, blister formation, and
hyperpigmentation will be assessed clinical